Search
Community and Stakeholder Committee
Current committee members
Gianluca Gaidano, Italy (Chair)
Helen Papadaki, Greece (Chair)
Donal McLornan, United Kingdom (Vice-Chair)
Meritxell Alberich Jordà, Czech Republic (Councilor)
Arndt Borkhardt, Germany (Research Committee representative)
Raul Córdoba Mascuñano, Spain (Councilor)
Margarita Guenova, Bulgaria (Councilor)
Mandy Lauw, The Netherlands (YoungEHA representative)
Ivo Touw, The Netherlands (Education Committee…
Sponsor and Fundraising Committee
Current committee members
Martin Dreyling, Germany (Chair)
Claire Harrison, United Kingdom (Vice-Chair)
Igor Aurer, Croatia (SWG Committee representative)
Arndt Borkhardt, Germany (Research Committee representative)
Konstanze Döhner, Germany (Education Committee representative)
Kirsten Grønbæk, Denmark (Councilor)
Frank Leebeek, The Netherlands (Councilor)
Mariane de Montalembert, France (Councilor)
David Rees, United Kingdom (Education…
Red Cells and Iron
This SWG covers the clinical areas of inherited and acquired disorders of the erythrocyte and iron metabolism.
Read moreExpert opinions for COVID-19 vaccination in patients with non-malignant hematologic diseases
Carlo Dufour, Helen Papadaki, Alan Warren, Colm Bradley, Cristina Mecucci, Jan Palmblad, Cornelia Zeidler, Francesca Fioredda, Sam Salek, Brigitte Schlegelberger and Daniela Guardo, on behalf of the EHA SWG on Granulocytes and Constitutional Marrow Failure Disorders; Carlo L.
Read moreEHA joins ESMO in calling for EU action on shortages of essential medicines
EHA joins ESMO in calling for EU action on shortages of essential medicines
The European Hematology Association (EHA) has endorsed and signed a collective Call to Action, prepared by the European Society for Medical Oncology (ESMO), on shortages of inexpensive, essential…
EHA-Baltic Hematology Tutorial in Estonia provides European-level expertise to local hematologists
EHA partnered with three Baltic societies on October 18 and 19 to provide European-level expertise to local hematology trainees and experienced hematologists.
Read moreDaratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study
Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.
Read morePromising results in trials with non-chemotherapy treatments for Leukemias to be presented at the 18th Congress of the European Hematology Association in Stockholm, June 13-16, 2013
What is new? Current investigations are aimed at evaluating the use of monoclonal antibodies (mAB). These mABs bind to specific molecules (antigens) found on leukemic cells. This results in immune destruction of the leukemic cells.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- »